Limits...
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.

Payer J, Brazdilova K, Jackuliak P - Drug Healthc Patient Saf (2010)

Bottom Line: An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis.Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures.We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

View Article: PubMed Central - PubMed

Affiliation: 5th Department of Internal Medicine, Medical Faculty of Comenius University and Faculty Hospital Bratislava, Bratislava, Slovakia.

ABSTRACT
An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures. In this review, we summarize the currently available methods of prevention and the treatment of glucocorticoid-induced osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

No MeSH data available.


Related in: MedlinePlus

Diagnostic and therapeutic steps in making decisions for the prevention of glucocorticoid-induced osteoporosis. Reproduced from Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324–325. Copyright © 2004, with permission from BMJ Publishing Group Ltd.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108700&req=5

f2-dhps-2-049: Diagnostic and therapeutic steps in making decisions for the prevention of glucocorticoid-induced osteoporosis. Reproduced from Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324–325. Copyright © 2004, with permission from BMJ Publishing Group Ltd.

Mentions: The stream diagram (Figure 2) shows the diagnostic and therapeutic steps in making decisions for the prevention of GIOP. Factors that influence this decision include the dose of glucocorticoids and the presence of other risk factors such as age, sex, previous fracture, and BMD. The main message is that treatment with bisphosphonates should be started immediately in patients at high risk (high dose of glucocorticoids, prevalent fracture, postmenopausal women, and elderly men).


Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.

Payer J, Brazdilova K, Jackuliak P - Drug Healthc Patient Saf (2010)

Diagnostic and therapeutic steps in making decisions for the prevention of glucocorticoid-induced osteoporosis. Reproduced from Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324–325. Copyright © 2004, with permission from BMJ Publishing Group Ltd.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108700&req=5

f2-dhps-2-049: Diagnostic and therapeutic steps in making decisions for the prevention of glucocorticoid-induced osteoporosis. Reproduced from Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324–325. Copyright © 2004, with permission from BMJ Publishing Group Ltd.
Mentions: The stream diagram (Figure 2) shows the diagnostic and therapeutic steps in making decisions for the prevention of GIOP. Factors that influence this decision include the dose of glucocorticoids and the presence of other risk factors such as age, sex, previous fracture, and BMD. The main message is that treatment with bisphosphonates should be started immediately in patients at high risk (high dose of glucocorticoids, prevalent fracture, postmenopausal women, and elderly men).

Bottom Line: An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis.Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures.We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

View Article: PubMed Central - PubMed

Affiliation: 5th Department of Internal Medicine, Medical Faculty of Comenius University and Faculty Hospital Bratislava, Bratislava, Slovakia.

ABSTRACT
An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures. In this review, we summarize the currently available methods of prevention and the treatment of glucocorticoid-induced osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

No MeSH data available.


Related in: MedlinePlus